Legal Representation
Attorney
Gordon M. Wright
USPTO Deadlines
Next Deadline
1923 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-05)
Due Date
November 05, 2030
Grace Period Ends
May 05, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 5, 2024 | NRCS | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 5, 2024 | R.SR | A | REGISTERED-SUPPLEMENTAL REGISTER | Loading... |
| Sep 26, 2024 | CNTA | O | APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER | Loading... |
| Sep 9, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Sep 9, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 9, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 14, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 14, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 14, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 5, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 5, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 5, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 9, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 9, 2024 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 9, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 4, 2024 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Mar 4, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 4, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 5, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Dec 5, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Dec 5, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Oct 10, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 10, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 10, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Aug 7, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 7, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 7, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 28, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 17, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 24, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products and preparations containing active pharmaceutical ingredients, namely, pharmaceutical grade Heparin Sodium, pharmaceutical grade Pancreatin, and pharmaceutical grade Pancrealipase, for use in humans and animals for the prevention and treatment of thrombotic events and to treat pancreatic insufficiency and related diseases; Pharmaceutical products and preparations, namely, anticoagulants; pharmaceutical products and preparations for the testing, sampling and identification of viruses, namely, medical diagnostic reagents and assays for testing of body fluids; Chemical preparations for sanitary use; Chemical preparations for treating mildew; Diagnostic preparations for medical purposes; Injectable pharmaceuticals for treatment of anaphylactic reactions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for treating thyroid conditions; Pharmaceutical preparations for wounds; Diagnostic preparations for use with medical devices; Pharmaceutical preparations for use in coating medical devices to prevent blood clotting and thrombotic events; Pharmaceutical preparations for ophthalmological use, namely, for treating eye diseases and disorders
First Use Anywhere:
Jan 1, 1976
First Use in Commerce:
Jan 1, 1976
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"SCIENTIFIC PROTEIN"